Cadila Healthcare shares rise 3% on DCGI nod to Phase III clinical trials of COVID-19 vaccine

In Phase II, the vaccine ZyCoV-D was found to be safe and elicited a strong immunogenic response.
04-01-2021
Bigul

CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Please find enclosed a copy of press release dated January 3, 2021 'Zydus Cadila receives approvals from the DCGI to start Phase III Clinical Trial of ZyCoV-D- fully indigenously developed vaccine'.
03-01-2021
Bigul

What sets Zydus Cadila apart among indigenous players in Covid vaccine race

The company says the stability of the vaccine is one of its biggest advantages amid dry runs of mass vaccination programmes being conducted in some states
02-01-2021

Zydus Cadila receives DCGI nod for NAFLD drug in India

The Drug Controller General of India (DCGI) has approved the new drug application (NDA) for Saroglitazar Mg for the treatment of non-alcoholic fatty liver disease (NAFLD) in India, Zydus Cadila said in a regulatory filing.
30-12-2020
Bigul

CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Zydus announces the approval of Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease in India
30-12-2020

Zydus Cadila plans to test its COVID-19 vaccine on 30,000 volunteers in late stage trial

Cadila Healthcare said its vaccine was found to be well tolerated and immunogenic in the Phase I/II clinical trials.
24-12-2020
Bigul

CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Zydus Cadila submits Phase I/II clinical trial data of ZyCoV-D, seeks nod to start Phase III Clinical Trials
24-12-2020
Next Page
Close

Let's Open Free Demat Account